SIMPADICO - Study of Immune Modulation Therapy in Peripheral Arterial Disease and Intermittent Claudication Outcomes
NCT00111826 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 500
Last updated 2010-03-31
Summary
The purpose of this study is to assess the effects of the Celacade™ system in patients with intermittent claudication.
Conditions
- Peripheral Arterial Disease
- Arterial Occlusive Diseases
- Intermittent Claudication
Interventions
- DEVICE
-
Celacade™ system
Sponsors & Collaborators
-
Vasogen
lead INDUSTRY
Principal Investigators
-
Michael E Shannon, MD · Vasogen Inc.
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 40 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-01-31
- Completion
- 2005-12-31
More Related Trials
-
A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication
NCT01131013 ·Status: COMPLETED ·Phase: PHASE2
-
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks
NCT00695305 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Tolerability of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease
NCT01157156 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease
NCT00443287 ·Status: COMPLETED ·Phase: PHASE2
-
Prostaglandin E1 in Outpatients With Intermittent Claudication
NCT01263925 ·Status: COMPLETED ·Phase: PHASE3
-
Hepatocyte Growth Factor to Improve Functioning in PAD
NCT03363165 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease.
NCT00798005 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Cilostazol Endothelial Progenitor Cells and Collateral Formation in Peripheral Occlusive Artery Disease (PAOD)
NCT01952756 ·Status: COMPLETED ·Phase: PHASE4
-
MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
NCT06409949 ·Status: RECRUITING ·Phase: NA
-
Cilostazol After Lower Extremity Arterial Revascularization Trial
NCT02374957 ·Status: TERMINATED ·Phase: PHASE4
-
A Trial of Alirocumab and Plaque Regression in Peripheral Arterial Disease
NCT02959047 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of NCX4016 on Walking Distance in Patients With Peripheral Arterial Occlusive Disease (PAOD)
NCT01256775 ·Status: COMPLETED ·Phase: PHASE2
-
Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?
NCT02983214 ·Status: COMPLETED ·Phase: PHASE4
-
Stem Cell Mobilization by G-CSF to Treat Severe Peripheral Artery Disease
NCT00797056 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Efficacy Study of Oral L-Citrulline in Patients Taking Simvastatin With Peripheral Arterial Disease
NCT00351286 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication
NCT03194776 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication
NCT00117650 ·Status: COMPLETED ·Phase: PHASE2
-
EW-A-401 to Treat Intermittent Claudication
NCT00080392 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)
NCT01679990 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial of Ischemic Preconditioning in Raynaud's Phenomenon (RP)
NCT02506062 ·Status: COMPLETED ·Phase: NA
-
Clinical Trial for Evaluation of Vermillion's Blood Test to Predict the Probability of Peripheral Artery Disease
NCT01336426 ·Status: COMPLETED
-
Gene Expression and Tolerability Study of NV1FGF in Patients With Peripheral Artery Occlusive Disease Planned to Undergo Major Amputation
NCT01157143 ·Status: COMPLETED ·Phase: PHASE1
-
Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
NCT03304821 ·Status: COMPLETED ·Phase: PHASE2
-
Shockwave Lithoplasty DISRUPT Trial for PAD (DISRUPT PAD 2)
NCT02369848 ·Status: COMPLETED ·Phase: NA
-
Recombinant SeV-hFGF2/dF Injection for PAOD
NCT03668353 ·Status: UNKNOWN ·Phase: PHASE1